Drug Profile
SCB 2019
Alternative Names: 2019-nCoV S-Trimer vaccine - Clover Biopharmaceuticals; CpG-1018/Alum; Protein-based COVID-19 S-trimer vaccine - Clover Biopharmaceuticals; recombinant 2019-nCoV S protein subunit-trimer vaccine - Clover Biopharmaceuticals; Recombinant S subunit trimer vaccine - Clover Biopharmaceuticals; Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine - Clover Biopharmaceuticals; S-trimer COVID-19 vaccine; S-Trimer vaccine - Clover Biopharmaceuticals; SCB 2019 (CpG 1018/Alum); SCB-2019Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator Clover Biopharmaceuticals
- Class Adjuvants; COVID-19 vaccines; Recombinant proteins; Subunit vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Australia (IM)
- 23 Apr 2023 Clover Biopharmaceuticals completes the phase II/III SPECTRA trial in COVID-2019 infections (Prevention) in Belgium, Germany, Brazil, Colombia, Philippines, and South Africa (IM) (NCT04672395)
- 15 Dec 2022 Clover Biopharmaceuticals withdraws a phase II/III trial in COVID-2019 infections (Prevention, In infants, In neonates, In adolescents, In children) in Colombia (IM), during the EC submission process prior to the enrolment (NCT05193279)